| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
5,910,000 |
| Market
Cap: |
1.15(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.142 - $0.3399 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Vyant Bio is a biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. Co.'s central nervous system (CNS) drug discovery platform is designed to: elucidate disease pathophysiology; formulate key therapeutic hypotheses; identify and validate drug targets, cellular assays, and biomarkers to guide candidate molecule selection; and guide clinical trial patient selection and trial design. Co.'s programs are focused on identifying small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome, CDKL5 Deficiency Disorders and Parkinson's Disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
765 |
| Total Sell Value |
$0 |
$0 |
$0 |
$1,021 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
1 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Yeh Yung-Ping |
Director |
– • – |
2022-03-30 |
4 |
A |
$0.00 |
$0 |
D/D |
43,478 |
56,240 |
|
- |
|
| Harris Geoffrey E. |
Director |
– • – |
2022-01-18 |
4 |
A |
$1.31 |
$5,312 |
D/D |
4,055 |
8,303 |
|
- |
|
| Fletcher R John |
Director |
– • – |
2022-01-18 |
4 |
A |
$1.31 |
$4,875 |
D/D |
3,721 |
12,397 |
|
- |
|
| Hansen Paul R. |
Director |
– • – |
2022-01-18 |
4 |
A |
$1.31 |
$3,749 |
D/D |
2,862 |
685,720 |
|
- |
|
| Boehm Marcus |
Director |
– • – |
2022-01-18 |
4 |
A |
$1.31 |
$7,500 |
D/D |
5,725 |
5,725 |
|
- |
|
| Horobin Joanna |
Director |
– • – |
2022-01-18 |
4 |
A |
$1.31 |
$6,999 |
D/D |
5,343 |
5,343 |
|
- |
|
| Boehm Marcus |
Director |
– • – |
2021-12-06 |
4 |
B |
$1.69 |
$8,450 |
I/I |
5,000 |
128,786 |
2.1 |
-36% |
|
| Roberts John A |
Chief Executive Officer |
• – – |
2021-11-24 |
4 |
B |
$2.02 |
$10,100 |
D/D |
5,000 |
39,807 |
2.74 |
-37% |
|
| Lafrence Andrew D.c. |
Chief Financial Officer |
• – – |
2021-11-23 |
4/A |
B |
$2.00 |
$9,998 |
D/D |
5,000 |
34,292 |
2.74 |
- |
|
| Hansen Paul R. |
Director |
– • – |
2021-11-09 |
4 |
A |
$0.00 |
$0 |
D/D |
6,783 |
159,778 |
|
- |
|
| Fremeau Robert Thomas Jr. |
Chief Scientific Officer |
• – – |
2021-10-28 |
4 |
B |
$2.19 |
$2,190 |
D/D |
1,000 |
1,000 |
2.66 |
-48% |
|
| Boehm Marcus |
Director |
– • – |
2021-10-27 |
4 |
AB |
$2.10 |
$10,500 |
I/I |
5,000 |
123,786 |
|
-41% |
|
| Boehm Marcus |
Director |
– • – |
2021-09-29 |
4 |
AB |
$2.44 |
$12,200 |
I/I |
5,000 |
118,786 |
|
-51% |
|
| Boehm Marcus |
Director |
– • – |
2021-08-25 |
4 |
AB |
$2.58 |
$12,878 |
I/I |
5,000 |
113,786 |
|
-48% |
|
| Roberts John A |
Chief Executive Officer |
• – – |
2021-08-23 |
4 |
B |
$2.41 |
$25,078 |
D/D |
10,406 |
34,807 |
2.74 |
-40% |
|
| Hansen Paul R. |
Director |
– • – |
2021-08-19 |
4 |
B |
$2.35 |
$47,000 |
D/D |
20,000 |
617,957 |
2.39 |
-41% |
|
| Boehm Marcus |
Director |
– • – |
2021-07-28 |
4 |
AB |
$2.92 |
$14,624 |
I/I |
5,000 |
108,786 |
|
-46% |
|
| Boehm Marcus |
Director |
– • – |
2021-06-30 |
4 |
AB |
$3.76 |
$18,825 |
I/I |
5,000 |
103,929 |
|
-29% |
|
| Boehm Marcus |
Director |
– • – |
2021-06-30 |
4/A |
AB |
$3.76 |
$18,825 |
I/I |
5,000 |
103,786 |
|
- |
|
| Boehm Marcus |
Director |
– • – |
2021-05-28 |
4 |
GD |
$0.00 |
$0 |
I/I |
5,000 |
98,929 |
|
- |
|
| Boehm Marcus |
Director |
– • – |
2021-05-28 |
4/A |
AB |
$3.68 |
$18,400 |
I/I |
5,000 |
98,786 |
|
- |
|
| Boehm Marcus |
Director |
– • – |
2021-05-28 |
4 |
AB |
$3.68 |
$18,400 |
D/D |
5,000 |
98,929 |
|
-38% |
|
| Roberts John A |
Chief Executive Officer |
• – – |
2021-05-26 |
4 |
B |
$3.55 |
$24,996 |
D/D |
7,041 |
312,117 |
2.74 |
-38% |
|
| Roberts John A |
Chief Executive Officer |
• – – |
2021-05-24 |
4 |
B |
$3.38 |
$25,147 |
D/D |
7,440 |
305,076 |
2.74 |
-36% |
|
| Fletcher R John |
Director |
– • – |
2021-05-24 |
4 |
B |
$3.39 |
$51,835 |
I/I |
15,300 |
30,300 |
2.1 |
-36% |
|
174 Records found
|
|
Page 2 of 7 |
|
|
